KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00. The downgrade reflects a shift in the investment firm's perspective on the ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Catherine Isted, an experienced healthcare CFO with over 25 years in life sciences, appointed as CFO effective February 24, 2025Current CFO ...

Co., Inc. (NYSE:MRK), recently purchased 2,832.861 shares of the company's common stock. The acquisition, valued at approximately $249,999, was completed at a price of $88.25 per share. Following this ...

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...

Whether improving the quality of life or the quality of our environment, life and health science students really do make a difference. Well-established links with government agencies, public bodies, ...